Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Biogen Idec presents positive data for investigational Alzheimer's disease treatment aducanumab (BIIB037)

Biogen Idec has announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive… Read & Research Alzheimer’s More

Leave a Reply